NIH clinical trial evaluating mixed COVID-19 vaccine schedules begins
Trial to evaluate safety, immunogenicity of various vaccine booster regimens.
Source: nih.gov
Page 38 - Valuating News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Valuating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Valuating Today - Breaking & Trending Today
Novartis Pharma AG: Novartis reports one year results of Phase III MERLIN study evaluating Beovu every four week dosing and provides update on Beovu clinical program
Beovu (brolucizumab) met MERLIN's primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept
Source: finanznachrichten.de
OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi in Combination with Opdivo (nivolumab) in Non-Small Cell Lung Cancer
This clinical trial will be sponsored and conducted by the Italian Oncology Foundation FoRT and supported by Bristol Myers Squibb and OSE Immunotherapeutics. The study will explorethe strategy
Source: finanznachrichten.de
Horizon Therapeutics plc Initiates ADVANCE Trial Evaluating KRYSTEXXA (pegloticase injection) with Methotrexate for People Who Previously Developed Anti-Drug Antibodies on KRYSTEXXA Monotherapy
(0) -- Trial evaluates opportunity to improve outcomes based on emerging data that immunomodulation may offer clinical benefit -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in the ADVANCE trial evaluating the concomitant use of KRYSTEXXA (pegloticase injection) with methotrexate for people with uncontrolled gout who were not able to achieve a complete response when previously treated with KRYSTEXXA monotherapy. For people with chronic gout refractory to conventional therapies (uncontrolled gout), KRYSTEXXA offers a unique mechanism of action that co...
Source: finanznachrichten.de
SIFI Initiates Patient Enrollment in Phase II Trial evaluating Pro-ocular in Dry Eye Disease
SIFI Initiates Patient Enrollment in Phase II Trial evaluating Pro-ocular in Dry Eye Disease ProGIFT is a 3 arms, multicenter, randomized, double-masked clinical trial in Italy. CATANIA, Italy, April 27, 2021 /PRNewswire/ -- SIFI announced today the enrollment of the first patients in the ProGIFT trial (NCT04645446), which aims at evaluating the safety and efficacy of Pro-ocular, a progesterone based topical gel in patients with Dry Eye Disease (DED). ProGIFT (NCT04645446) is a multicenter, randomized, double-masked, placebo-controlled Phase II clinical trial comparing different concentration...
Source: finanznachrichten.de